A Phase 1/2 interventional study of WVE-006 in Alpha-1 Antitrypsin Deficiency, sponsored by Wave Life Sciences USA, Inc.. Recruiting at 9 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Wave Life Sciences USA, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom — 8 open to participants now, 11 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · United Kingdom.
Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, this one is the 15th largest by planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2024, is one of 4 in phase 1/2, reaches primary completion later than 2 of the 10 other live ones, and was the 23rd registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →8 of the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom are open now. Recruiting first, the newest first:
Richmond Research Institute · Sites in United Kingdom
Ages 18+
Tessera Therapeutics, Inc. · Sites in United Kingdom, United States, Australia and 2 more countries
Ages 18–70
AIRNA Corporation · Sites in United Kingdom, Australia, Georgia and 6 more countries
Ages 18–74
Takeda · Sites in United Kingdom, United States, Austria and 3 more countries
Ages 18+
Beam Therapeutics Inc. · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18–75
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 6
First in 2003; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 54 across the 25 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 28 have an industry lead sponsor. The 10 most frequent:
Wave Life Sciences USA, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Wave Life Sciences USA, Inc. has 2 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07924462Richmond Research InstituteChronic Respiratory Disease Participant Engagement Study | 2027-08-01 |
| NCT06405633Wave Life Sciences USA, Inc.A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
Drug: WVE-006
RNA editing oligonucleotide
The proportion of participants with adverse events
Time frame: Up to 36 Weeks
Single Ascending Dose - Change from baseline in levels of serum M-AAT protein.
Time frame: Up to 12 Weeks
Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein
Time frame: Up to 24 Weeks
Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)
Time frame: Up to 12 Weeks
Single Ascending Dose - Maximum concentration of WVE-006 in plasma
Time frame: Up to 12 Weeks
Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)
Time frame: Up to 24 Weeks
Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax)
Time frame: Up to 24 Weeks
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Sep 2027, 38 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
alpha 1-Antitrypsin Deficiency →
Wave Life Sciences USA, Inc.